DK164552B - Analogifremgangsmaade til fremstilling af 1-oe2-carbalkoxy-4-(thienylcarboxamido)-phenoxyaa-3-amino-2-propanoler eller syreadditionssalte deraf - Google Patents
Analogifremgangsmaade til fremstilling af 1-oe2-carbalkoxy-4-(thienylcarboxamido)-phenoxyaa-3-amino-2-propanoler eller syreadditionssalte deraf Download PDFInfo
- Publication number
- DK164552B DK164552B DK326883A DK326883A DK164552B DK 164552 B DK164552 B DK 164552B DK 326883 A DK326883 A DK 326883A DK 326883 A DK326883 A DK 326883A DK 164552 B DK164552 B DK 164552B
- Authority
- DK
- Denmark
- Prior art keywords
- formula
- phenoxy
- propanol
- carboxamido
- tert
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 13
- 239000002253 acid Substances 0.000 title claims description 8
- 150000003839 salts Chemical class 0.000 title claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 33
- KFZMGEQAYNKOFK-UHFFFAOYSA-N 2-propanol Substances CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 150000001408 amides Chemical class 0.000 claims description 12
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims description 10
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 7
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 7
- -1 4 -methyl-2-thiophene-carboxamido Chemical group 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 150000003857 carboxamides Chemical group 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 229930192474 thiophene Natural products 0.000 claims description 3
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 2
- 229960004592 isopropanol Drugs 0.000 claims 9
- JZEHWMUIAKALDN-UHFFFAOYSA-N 1-amino-3-phenoxypropan-2-ol Chemical class NCC(O)COC1=CC=CC=C1 JZEHWMUIAKALDN-UHFFFAOYSA-N 0.000 claims 1
- HKKCYMCHJZENJO-UHFFFAOYSA-N 5-methylthiophene-2-carboxamide Chemical compound CC1=CC=C(C(N)=O)S1 HKKCYMCHJZENJO-UHFFFAOYSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 239000013078 crystal Substances 0.000 description 8
- 150000002118 epoxides Chemical class 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- KXHPPCXNWTUNSB-UHFFFAOYSA-M benzyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC1=CC=CC=C1 KXHPPCXNWTUNSB-UHFFFAOYSA-M 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 5
- 229940011051 isopropyl acetate Drugs 0.000 description 5
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 238000010908 decantation Methods 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- UBSYOISGGGOJIM-UHFFFAOYSA-N ethyl 5-[(5-methylthiophene-2-carbonyl)amino]-2-(oxiran-2-ylmethoxy)benzoate Chemical compound C=1C=C(OCC2OC2)C(C(=O)OCC)=CC=1NC(=O)C1=CC=C(C)S1 UBSYOISGGGOJIM-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- RFMMMVDNIPUKGG-YFKPBYRVSA-N N-acetyl-L-glutamic acid Chemical compound CC(=O)N[C@H](C(O)=O)CCC(O)=O RFMMMVDNIPUKGG-YFKPBYRVSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 1
- GWDMLLAHLJEAFN-UHFFFAOYSA-N ethyl 2-[2-hydroxy-3-(propan-2-ylamino)propoxy]-5-[(5-methylthiophene-2-carbonyl)amino]benzoate Chemical compound C1=C(OCC(O)CNC(C)C)C(C(=O)OCC)=CC(NC(=O)C=2SC(C)=CC=2)=C1 GWDMLLAHLJEAFN-UHFFFAOYSA-N 0.000 description 1
- YSINLZWWCSIQCK-UHFFFAOYSA-N ethyl 2-hydroxy-5-[(4-methylthiophene-2-carbonyl)amino]benzoate Chemical compound C1=C(O)C(C(=O)OCC)=CC(NC(=O)C=2SC=C(C)C=2)=C1 YSINLZWWCSIQCK-UHFFFAOYSA-N 0.000 description 1
- VCAQZNKKSQMFLM-UHFFFAOYSA-N ethyl 2-hydroxy-5-[(5-methylthiophene-2-carbonyl)amino]benzoate Chemical compound C1=C(O)C(C(=O)OCC)=CC(NC(=O)C=2SC(C)=CC=2)=C1 VCAQZNKKSQMFLM-UHFFFAOYSA-N 0.000 description 1
- LFVCVCYJMTVCMB-UHFFFAOYSA-N ethyl 5-[(4-methylthiophene-2-carbonyl)amino]-2-(oxiran-2-ylmethoxy)benzoate Chemical compound C=1C=C(OCC2OC2)C(C(=O)OCC)=CC=1NC(=O)C1=CC(C)=CS1 LFVCVCYJMTVCMB-UHFFFAOYSA-N 0.000 description 1
- YYKXJAPWQWTDNE-UHFFFAOYSA-N ethyl 5-[(5-chlorothiophene-2-carbonyl)amino]-2-(oxiran-2-ylmethoxy)benzoate Chemical compound C=1C=C(OCC2OC2)C(C(=O)OCC)=CC=1NC(=O)C1=CC=C(Cl)S1 YYKXJAPWQWTDNE-UHFFFAOYSA-N 0.000 description 1
- KIJMVBHXUCMHCF-UHFFFAOYSA-N ethyl 5-[(5-chlorothiophene-2-carbonyl)amino]-2-hydroxybenzoate Chemical compound C1=C(O)C(C(=O)OCC)=CC(NC(=O)C=2SC(Cl)=CC=2)=C1 KIJMVBHXUCMHCF-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 229940124591 thiazide-type diuretic Drugs 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
DK 164552B
Den foreliggende opfindelse angår .en analogifremgangsmåde til fremstilling af forbindelser med den nedenfor anførte almene formel I og deres syreadditionssalte.
I FR-A-1.543.689 beskrives forbindelser med strukturen 5 4
Λ \ ?R
\ OCH CHCH-NHR5 R6CONH^~ 'R3 I FR-A-2.458.548 beskrives forbindelser med strukturen 10 R9—IΜ H . .0-CH_-CH-CH^-NH-R7
ΤοΛλ-c-n-Q^ 2 iH
I EP-A-71.535 beskrives forbindelser med strukturen 15 Y X
j -f|—CH.-CONH—(/ y—0-CH«~CH~CH_-NHR3 ^
‘''s' \=/ iH
De nævnte kendte forbindelser udviser ^-blokerende 20 virkning.
I forhold hertil udviser forbindelserne med den nedenfor anførte almene formel I overraskende en særlig farmakologisk profil, idet de både har /3-blokerende egenskaber, der kan sammenlignes med egenskaberne af propranolol, og 25 diuretiske egenskaber, der kan sammenlignes med egenskaberne af forbindelser af thiazid-typen.
, 0 OOOR
-1 /—( r2-f -i-CONH— // 'A-O-CH.-CH-CH.-NH-R1 30 \—/ iH (I) formlen I har de anvendte symboler følgende betydning: R betyder en forgrenet eller uforgrenet alkylgruppe med 1-5 carbonatomer, især en ethylgruppe, 35 R1 betyder en ligekædet eller forgrenet alkylgruppe med 1-5 carbonatomer, især en isopropylgruppe eller en tert.butyl-gruppe, 2
DK 164552 B
betyder hydrogen, en ligekædet, forgrenet eller cyclisk mættet carbonhydridgruppe med 1-5 carbonatomer, halogen eller en tilkondenseret ring valgt blandt cyclohexyl og cyclopentyl, og carboxamidgruppen er bundet til thiophenrin-5 gen i 2- eller 3-stilling.
Fremgangsmåden ifølge opfindelsen er ejendommelig ved, at en base NH2-R1 (R1 har den ovenfor angivne betydning) omsættes med en forbindelse med den nedenfor anførte formel II i fraværelse af opløsningsmiddel eller i et sædvanligt 10 organisk opløsningsmiddel, såsom en alkohol, ved en temperatur mellem 20 og 150°C, hvorpå en dannet forbindelse med formlen I om ønsket omdannes til et syreadditionssalt deraf 0 R2-[jT^ 4--C0NH- ^ ^r-0-CH2-CH-CH2 (II)
^ COOR
2 (R og R har den ovenfor angivne betydning).
Generelt kan forbindelserne med formlen II fremstilles ved omsætning af en phenol med den almene formel 20 III med et epihalogenhydrin, især epichlorhydrin eller epibromhydrin. Phenolen med formlen III er i forvejen omdannet til et metalderivat ved hjælp af sædvanlige metalderivatiseringsmidler, såsom natriumhydroxid, kaliumhydroxid, et alkoholat eller natriumhydrid, i vandigt-alkoholisk eller alkoholisk medium eller i et opløsningsmiddel som dimethylformamid ved en temperatur mellem 20 og 150°C.
COOR
30 R2-\ -U-CONH- / \—OH (III) \_y 2 (R og R har den ovenfor angivne betydning).
Disse i og for sig kendte syntesemetoder giver dårligt 35 definerede forbindelser i ringe udbytter- De fremstilles derfor især ved en fremgangsmåde der består i at omsætte phenolen med formlen III med et overskud af epichlorhydrin 3
DK 164552 B
i nærværelse af et kvaternært ammoniumsalt, såsom benzyltri-methylammoniumchlorid, ved en temperatur på 110-130*C. Denne fremgangsmåde giver perfekt definerede krystallinske forbindelser i gode udbytter.
5 Forbindelserne med formlen III fremstilles ved en klassisk metode, der består i at omsætte syrechloridet af den tilsvarende thienylcarboxylsyre med en 4-amino-2-carbalkoxy-phenol i nærværelse af en base, såsom triethylamin, i et opløsningsmiddel, såsom 10 acetone eller benzen.
De ugiftige syreadditionssalte af forbindelserne med formlen I kan fremstilles ved omsætning af disse forbindelser med en uorganisk eller organisk syre ved i og for sig kendte metoder. Blandt syrer, der 15 er anvendelige til dette formål, kan der nævnes saltsyre, hydrogenbromidsyre, svovlsyre, phosphorsyre, p-toluensulfon-syre, methansulfonsyre, cyclohexylsulfaminsyre, oxalsyre, ravsyre, myresyre, maleinsyre, asparaginsyre, kanelsyre, glutaminsyre, N-acetylasparaginsyre, N-acetylglutaminsyre, 20 ascorbinsyre, æblesyre, fumarsyre, mælkesyre og benzoesyre .
De her omhandlede, hidtil ukendte forbindelser har bemærkelsesværdige farmakologiske egenskaber og kan anvendes i terapien som 3~blokkere af propranoJol·-25 -typen og som diuretika af thiazid-typen, eftersom de overraskende udviser disse to egenskaber samtidig, ved behandling af hypertension. Desuden er disse forbindelser cardioselek-tive og kun i ringe grad giftige.
En særlig foretrukket undergruppe IA af de her om-30 handlede forbindelser har formlen I, hvori carboxamidkæden er bundet til thiophenringen i 2-stilling til denne ring. Forbindelserne i denne gruppe har samtidig udmærkede diure-tiske og /?-blokerende egenskaber.
Det skal endvidere bemærkes, at undergruppen I B, 35 hvori carboxamidkæden er i 3-stilling, er forbindelser, der forener en god /3-blokerende aktivitet med en diuretisk ten- 4
DK 164552 B
dens.
Desuden har det vist sig, at de her omhandlede 2 forbindelser, hvori R betyder hydrogen eller 4-methyl, er særlig interessante. Disse forbindelser er især 5 overlegne i forhold til en 5-methyl-substituering af thiophen.
Forbindelserne I E, hvori carboxamidkæden er i 2 2-stilling til thioiiien,og R betyder hydrogen eller 4-methyl, er således ganske særlig interessante.
10 Inden for humanterapien kan forbindelserne med formlen I og deres ugiftige syreadditionssalte især indgives oralt. Til dette formål kan der anvendes kapsler eller tabletter indeholdende 50-300 mg aktiv forbindelse sammen med en fysiologisk acceptabel excipiens. De 15 omhandlede forbindelser har den fordel, at de gør behandlingen lettere. Desuden har forbindelserne I A i forhold til de kombinationer af β-blokkere og diuretika, der anvendes ved behandling af hypertension, den afgørende fordel, at de har en enestående farmakokinetik. Som 20 andre eksempler på mulige indikationer kan der nævnes angor, arytmi og hovedpine.
Fremgangsmåden ifølge opfindelsen belyses nærmere ved hjælp af de følgende eksempler.
25 Eksempel 1 1- [2-Carbethoxy-4- (5-methyl-2-thiophen- carboxamido) --phenoxy]-2,3-epoxypropan (formel II, R = .C^, R = 5-CH3) 30 I en kolbe opvarmes en blanding af 35 g 2- carbethoxy-4-(5-methyl-2-thio phen-carboxamido)--phenol og 175 ml epichlorhydrin til 110°C, hvorefter der tilsættes 2,9 g benzyltrimethylammoniumchlorid.
35 Derpå opvarmes reaktionsblandingen under tilbagesvaling 1 30 minutter, hvorefter den afkøles. Når
DK 164552 B
O
5 blandingens temperatur er faldet til 50°C, tilsættes der 200 ml vand og omrøres kraftigt. Efter dekantering ekstraheres den'vandige fase med 2 x 50 ml ether, og de organiske faser tørres over magnesiumsulfat, filtreres 5 og koncentreres under vakuum. Remanensen bliver fast i ether. Efter 3 vaskninger med 50 ml isopropyl-ether fås 30 g 1-[2-carbethoxy-4-(5-methyl-2-thiophen--carboxamido)-phenoxy]-2,3-epoxypropan i form af hvide krystaller med smp. 109°C.
10
Eksempel 2 1-[2-Carbethoxy-4-(5-methyl-2-thiophén-carboxamido)--phenoxy] -3-tert.butylamino-2--propanol 15 (formel I, R = c2ns' r1 = 3' r2 = 5-CH3) 14 g af det ifølge eksempel 1 fremstillede epoxid i 30 ml tert.butylamin og 100 ml ethanol opvarmes til tilbagesvaling i 8 timer i en kolbe. Den alkoholiske 20 opløsning koncentreres derefter under vakuum, og remanensen optages i 150 ml vand, 5 ml iseddike og 100 ml isopropylacetat. Den organiske fase fjernes ved dekantering, og den sure vandige fase neutraliseres med en ammoniakopløsning, hvorefter den ekstraheres med 25 2 x 50 ml chloroform. Efter tørring over magnesiumsulfat filtreres chloroformfasen og koncentreres under vakuum.
Den fremkomne olie optages varmt i isopropylacetat.
Opløsningen filtreres varmt og afkøles derefter. Det fremkomne udfældede produkt vaskes grundigt med 30 ether. Der fås til slut 4 g 1-[2-carbethoxy-4-(5- -methyl-2“ thiophen-carboxamido) -phenoxy]-3-tert .butyl-amino-2-propanol i form af hvide krystaller med smp. 110°C.
35
O
6
DK 164552 B
Eksempel 3 1-[2-Carbethoxy-4-(5-methyl-2-thiophen-carboxamido)--phenoxy]-3-isopropylamino-2-propanol 5 (formel I, R = C2H5, R1 = -CH(CH3)2, R2 = 5-CH3)
Der gås frem på samme måde som beskrevet i eksempel 2, idet tert.butylamin erstattes med isopropylamin. Der fås til slut en remanens, der efter omkrystallisation fra ethylacetat giver 6 g 1-[2-carbethoxy-4-(5-methyl- 10 -2- thiophen-carboxamido) -phenoxy] -3-isopropylamino-2--propanol i form af hvide krystaller med smp. 121°C.
Eksempel 4 1-[2-Carbethoxy-4-(5-chlor-2-thiophen-carboxamido)--phenoxy]-2,3-epoxypropan (formel II, R * C2H5' r2 = 5-C1)
Der gås frem på samme måde som beskrevet i 20 " r eksempel 1, men anvendes 11 g 2-carbethoxy-4-(5- -chlor-2-thiophen-carboxamido)-phenol, 60 ml epichlor- hydrin og 1 g benzyltrimethylammoniumchlorid. Der fås 7 g af en olie, der ikke krystalliserer, men anvendes i denne form.
25
Eksempel 5 1-[2-Carbethoxy-4-(5-chlor-2-thiophen-carboxamido)-phenoxy]--3-tert.butylamino-2-propanol-hydrochlorid 30 12 (formel I, R = C^, R = C(CH3)3, R = 5-Cl)
Den ifølge eksempel 4 fremstillede olie opløses i 50 ml tert.butylamin, og blandingen opvarmes under 35 tilbagesvaling i 8 timer. Der gås derefter frem på samme måde som beskrevet i eksempel 2. Der fås krystaller,
O
7
DK 164552 B
som optages i 100 ml acetone, hvortil der sættes 10 ml etherisk saltsyre. Efter frafiltrering af bundfaldet og vaskning med acetone og derefter med ether fås 700 mg 1-[2-carbethoxy-4-(5-chlor-2-thiophen-carboxamido)-phenoxy]-5 -3-tert.butylamino-2-propanolhydrochlorid i form af hvide krystaller med smp. 165°C.
Eksempel 6 1-[2-Carbethoxy-4-(4-methyl-2-thiophen-carboxamido)-phenoxy]- 10 „ -2,3-epoxypropan (formel II, R = C^, R2 = 4-CH3)
Der gås frem på samme måde som beskrevet i 15 eksempel 1. Ved anvendelse af 30 g 2-carbethoxy-4--(4-methyl-2-thiophen-carboxamido)-phenol, 3 g benzyl-trimethylammoniumchlorid og 150 ml epichlorhydrin fås der efter behandling en olie, der ekstraheres med 2 x 100 ml ether. Efter tørring af etherfasen og koncen- 20 trering under vakuum fås 12 g 1-[2-carbethoxy-4-(4--methyl-2-thiophen-carboxamido)-phenoxy]-2,3-epoxypropan i form af hvide krystaller med smp. 118°C.
Eksempel 7 25 1-[2-Carbethoxy-4-(4-methyl-2-thiophen-carboxamido)--phenoxy]-3-tert.butylamino-2-propanol-hydrochlorid (formel I, R = C2H5, R1 = -C(CH3)3, R2 = 4-CH3) 30
Der gås frem på samme måde som beskrevet i eksempel 2.
Ud fra 10 g af epoxidet fremstillet ifølge eksempel 6 og 50 ml tert.butylamin fås 6 g krystaller, der opløses i et minimum af ethanol. Der tilsættes derefter etherisk saltsyre til en pH-værdi på ca. 1, og bundfaldet fra- · skilles ved filtrering. Ved omkrystallisation fra ethanol fås 3,3 g 1-[2-carbethoxy-4-(4-methyl-2-thiophen- 35 0 8
DK 164552 B
-carboxamido)-phenoxy]-3-tert.butylamino-2-propanol--hydrochlorid i form af hvide krystaller med smp. 186°C.
Eksempel 8 5 l-[2-Carbethoxy-4-[2-(4,5,6,7-tetrahydro)-thianaphthen--carboxamido]-phenoxy]-2,3-epoxypropan (formel II, R = C2H5, R2 = 4,5-(CH2)4-, ) 10 På samme måde som i eksempel 1 fås der ud fra 2-carbeth- oxy-4-[2-(4,5,6,7-tetrahydro)-thianaphthen-carboxamido]-phenol, benzyltrimethylammoniumchlorid og epichlorhydrin l-(2-carb-ethoxy-4-[2-(4,5,6,7-tetrahydro)-thianaphthen-carboxamido] -phenoxy]-2,3-epoxypropan.
15
Eksempel 9 1-[2-Carbethoxy-4-[2-(4,5,6,7-tetrahydro)-thianaphthen--carboxamido]-phenoxy]-3-tert.-butylamino-2-propanol 20 (formel I, R = C2H5, R1 = C(CH3)3, R2 = 3,4-(CH2) 4~,)
Idet der gås frem på samme måde som beskrevet i eksempel 2, men gås ud fra det ifølge eksempel 8 fremstillede epoxid og tert.-butylamin, fås 1-[2-carbethoxy-4-[2-25 -(4,5,6,7-tetrahydro)-thianaphthen-carboxamido]-phenoxy]--3-tert.-butylamino-2-propanol.
Eksempel 10 1-[2-Carbethoxy-4-(2-thienyl-carboxamido) —phenoxy]-2,3-30 -epoxypropan (formel II, amid i 2-stilling , R = C2H5) * I en kolbe opvarmes en blanding af 10 g 4-(2-thienyl- -carboxamido)-2-carbethoxy-phenol og 60 ml epichlorhydrin til 110°C, hvoreftér der tilsættes 0,9 g benzyltrimethyl- 35 9
O
DK 164552 B
airmon iumchl or id. Blandingen opvarmes derefter under tilbagesvaling 1/2 time, hvorefter den afkøles. Når temperaturen er faldet til 50°C, tilsættes 150 ml vand. Reaktionsblandingen omrøres godt, hvorefter den ekstraheres 5 med 2 x 50 ml ether. Etherfaserne tørres og inddampes til tørhed. Den fremkomne remanens krystalliserer i ether og giver såldes 8 g 1-[2-carbethoxy-4-(2-thienvl-carb-oxamido)-phenoxy]-2,3-epoxypropan med smp. 110 C.
10 Eksempel 11 1- [2-Carbethoxy-4- (3-thienyl-carboxamido) -phenoxy] -2,3--epoxypropan (formel II, amid i 3-stilling, R = C2H5) 15
Idet der gås frem på samme måde som beskrevet i eksempel 10, men gås ud fra 13 g 4-(3-thienyl-carboxamido)-2--carbethoxy-phenol, 70 ml epichlorhydrin og 1 g benzyl-trimethylammoniumchlorid, fås 8 g l-[2-carbethoxy-4-(2-20 -thienyl-carboxamido)-phenoxy]-2,3-epoxypropan med smp.
119°C.
Eksempel 12 1-[2-Carbethoxy-4-(2-thienyl-carboxamido)-phenoxy]-3-iso-25 propylamino-2-propanol (base) (formel I, amid i 2-stilling, R = C^, R1 = -CH(CH3)2) 8 g af det ifølge eksempel 10 fremstillede epoxid og 30 10 ml isopropylamin i 50 ml ethanol opvarmes under omrøring til 50°c i en kolbe. Efter 8 timers opvarmning til 50°C koncentreres den alkoholiske opløsning under vakuum, og remanensen optages i en blanding af 100 ml isopropyl-acetat og 200 ml vand. I kulden tilsættes derefter 3 ml 35 iseddike, og der omrøres, indtil der fås et uklart medium. Isopropylacetatet fjernes derpå ved dekantering, og den eddikesure opløsning gøres basisk med ammoniak i kulden.
10
DK 164552 B
o
Den basiske fase ekstraheres med 2 x 50 ml chloroform.
Efter tørring og koncentrering under vakuum af den organiske fase fås en pastaagtig remanens, der krystalliserer i 50 ml ether, hvorved der fås 4,5 g l-[2-carb- c ethoxy-4-(2-thienyl-carboxamido)-phenoxy]-3-isopropyl-amino-2-propanol med smp. 108°C.
Eksempel 13 1-[2-Carbethoxy-4-(2-thienyl-carboxamido)-phenoxy-3-10 -tert.-butylamino-2-propanol (base) (formel I, amid i 2-stilling, R = C2H5' r1 = -CfCH^^)
Idet der gås frem som beskrevet i eksempel 12, men 15 gås ud fra 8 g af epoxidet beskrevet i eksempel 10 og 10 ml tert.-butylamin, fås 3,5 g 1-[2-carbethoxy-4-(2--thienyl-carboxamido)-phenoxy]-3-tert.-butylamino-2-pro-parol med smp. 125°C.
20
Eksempel 14 1-[2-Carbethoxy-4-(3-thienyl-carboxamido)-phenoxy-3-iso-propylamino-2-propanol (base) (formel I, amid i 3-stilling, R = C~Ec/ R = -CH(CH_)_) 25 2 5 3 2
Idet der gås frem som beskrevet i eksempel 12, men gås ud fra 8 g af epoxidet fremstillet ifølge eksempel 11, fås 5'5 g 1-12-carbethoxy-4-(3-thienyl-carboxamido)-phenoxy)- -3-isopropylamino-2-propanol med smp. 132°C.
30 35 11
O
DK 164552 B
Eksempel 15 1-[2-Carbethoxy-4-(3-thienyl-carboxamido)-phenoxy]-3--tert.-butylamino-2-propanol (base) 5 1 (formel I, amid i 3-stilling, R = C2H5, R = -C(CH3)2)
Idet der gås frem som beskrevet i eksempel 13, men gås ud fra 5,6 g af epoxidet fremstillet ifølge eksempelil, fås 3,5 g 1-[2-carbethoxy-4-(3-thienyl-carboxamido)-10 -phenoxy]-3-tert.-butylamino-2-propanol med smp. 126°c.
Eksempel 16 1-[2-Carbomethoxy-4-(2-thienyl-carboxamido)-phenoxy-2,3-15 -epoxypropan (formel II, amid i 2-stilling, R = CH^)
Idet der gås frem som beskrevet i eksempel 10, men 20 gås ud fra 35 g 2-carbomethoxy-4-(2-thienyl-caroxamido)- -phenol, 210 ml epichlorhydrin og 3 g benzyltrimethyl- ammoniumchlorid, fås der efter omkrystallisation af den rå olie fra isopropylacetat 17 g 1-[2-carbomethoxy-4-- (2-thienyl-carboxamido) -phenoxy] -2,3-epoxypropan med 25 smp. 131°C.
Eksempel 17 1-[2-Carbomethoxy-4-(2-thienyl-carboxamido)-phenoxy]-3--tert.-butylamino-2-propanol (base) 30 (formel I, amid i 2-stilling, r = ch , r1 = -C(CH.).)
Idet der gås frem som beskrevet i eksempel 12, men gås ud fra 3,6 g af epoxidet beskrevet i eksempel 16 og 35 io ml tert.-butylamin, fås 1 g 1-[2-carbomethoxy-4-(2- -thienyl-carboxamido)-phenoxy]-3-tert.-butylamino-2-propanol med smp. 136°C.
Tabel
O
12
DK 164552 B
Beskrevne forbindelser 5 C00C„H_ Referencenummer 10 '—/ ύ COOC.H.
jj-?. _/ 2 5 CH3
Sksarpel 2 ^CONB-/Q Voc^-CH-CH2-NH-C-CHg 788-56
15 W °H
_ COOC_H_ fj [j /-( /-CH,
Eksempel 3 CH^g /L CONH-'ΛΛ \ OCH, CH-CH2-NH-CH 788-57 '-' “ OH ^CH3 20 __i /cooc2h5
Ekssnpel 4 C J^s^OTNH-^QV-0 CH2'CH-CH2
'-' O
25-- COOC2H5 30 Ekserrpel Ξ Cl-I^g JLcONH-/q\- 0CH2- CH-CH2 NH-C-CHg, HC1 788-58 -' OH CH3 C^3 COOC?H5 35 Eksempel 6 t s J- CONH-^Q^- 00¾
Tabel (fortsat)
DK 164552B
o 13
Reference nummer 5 m COOCÆ.
-3Ί~Ϊ) /~i " ' ?3
Eksempel 7 y y—CONH <0> 0CH2· CH CH2 NH-C-OLj, HCT 788-59 '-' OH CH^ 10 cooc2h5
Eksempel 8 J1x0NH-/q\- O CH2 CH-CH2 \-' o 15 C00CoHc -j _/ 2 5
Eksempel 9 JLconh/q)-00^- CH CH2 NH-C-Ci^
'-' OH CH
3 · 20 ^COO-t C (_
Eksempel 10 [i Γ /— \ y-co ::u-/ .Y-c-ck-ch-ch
Xs-^ \J 1 V ‘ 25 Eksempel 11 -CO NU ~J A-O-CHrCH-CK.
• Π v ' CCO -£ c
Eksempelvis!· Γ Π 9·* 3° i 11 I I , i SH-/ \—0 - C:i - C H - C K -: < H —<^ /SS-i3 ,3 35 \coo-ic _ 14
O
Tabel (fortsat)
DK 164552 B
Reference nummer
5 Eksempel 13. —_ ,-, OH
j J I LcO KU—/ \-0-CHnCH-CHr NH—1— 7S8-A2 V V z 1 1 I \ ! . COO-> c i
Eksanpel 14 i.
10 i /=\ CO HH-/. \-0 CH-CH-Cli-RH <" 5130-Ci -/ \ // 2| 2 ' U jj coo ic ___5^___
Eksanpel 15
15 ' OH
Ir ^ ·' I I
JZZ >!·-:_/' '\-C~CHr-CH-CH-NH-T— 5130-01 _ ^Ji Γ. '__________ __s__ 20
Ekssnpel 16 - 0 - I ί /7Λ_ Λ \ jJ— CO-NH-f Q jr~0 CH,-CH-CH2 ^ COO-CH3 25
Eksempel 17 _ X0CCH„ II i \ s co ·Q >-o-ch_- ch- ch - hh — 7S8-is S \ ^ 1 - \ -
-' OH
30 35
Claims (9)
1. Analogifremgangsmåde til fremstilling af l-[2--carbalkoxy-4-(thienylcarboxamido]phenoxy-3-amino-2-propano-ler med formlen (I) eller syreadditionssalte deraf 5 COOR R 2_f Ij--CONH-/ \-0-CH2-ai-CH2-NH-R1 \=J OH hvori 10. betyder en forgrenet eller uforgrenet alkylgruppe med 1-5 carbonatomer, især en ethylgruppe, R1 betyder en ligekædet eller forgrenet alkylgruppe med 1-5 carbonatomer, især en isopropylgruppe eller en tenrt.butyl-gruppe,
15 R2 betyder hydrogen, en ligekædet, forgrenet eller cyclisk mættet carbonhydridgruppe med 1-5 carbonatomer, halogen eller en tilkondenseret ring valgt blandt cyclohexyl og cyclopentyl, og carboxamidgruppen er bundet til thiophenrin-gen i 2- eller 3-stilling, 20 kendetegnet ved, at en base med formlen NH2R1 hvori R1 har den ovenfor angivne betydning, omsættes med en forbindelse med formlen (II) Q 0 O-CHj-CH-CKj (II) COOR hvori R og R2 har den ovenfor angivne betydning, i fraværelse 30 af opløsningsmiddel eller i et sædvanligt organisk opløsningsmiddel, såsom en alkohol, ved 20-150°C, hvorpå en dannet forbindelse med formlen I om ønsket omdannes til et syreadditionssalt deraf.
2. Fremgangsmåde ifølge krav 1, kendetegnet 35 ved, at forbindelserne med formlen (II) er fremstillet ved omsætning af en phenol med formlen (III) DK 164552 B COOS. r2—jr ri-co:ni/ y_QH (iii) 5 kS ^ Vj/ hvori R og R2 har den i krav 1 angivne betydning, med et overskud af epichlorhydrin i nærværelse af et kvaternært ammoniumsalt, såsom et benzyltriammoniumsalt, ved 110-130“C.
3. Fremgangsmåde ifølge krav 1 eller 2, kende tegnet ved, at forbindelserne (I) tilhører undergruppen (IA), hvori carboxamidkæden er i 2-stilling til thiophen.
4. Fremgangsmåde ifølge krav 1 eller 2, kendetegnet ved, at forbindelserne (I) tilhører undergruppen 15 (IB), hvori carboxamidkæden er i 3-stilling til thiophen.
5. Fremgangsmåde ifølge krav 1 eller 2, kendetegnet ved, at forbindelserne (I) er valgt blandt følgende: 1-[2-carbethoxy-4-(5-methyl-2-thiophen-carboxamidp)--phenoxy]-3-tert.-butylamino-2-propanol
20 CH3 (formel I, R = C2Hg, R^ = C-CH^, R2 = CH^ i 5-stilling ) ch3 1-[2-carbethoxy-4-(5-methy1-2-thiophen-carboxamido)-25 -phenoxy]-3-isopropylamino-2-propanol ^CH3 (formel I, R = C2H5, R1 = -CH^ , R2 = CH3 i 5-stilling) ch3 30 1-[2-carbethoxy-4-(5-chlor-2-thiophen-carboxamido)- -phenoxy] -3-tert. -butylamino-2-propanol -hydrochlorid CH3 (formel I, R = C2H3, R^ =-C-CH3, R2 = Cl i 5-stilling) in3 35 O DK 164552 B 1-[2-carbethoxy-4-(4-methyl-2-thiophen-carboxamido)--phenoxy] -3-tert. -butylamino-2-propanol-hydrochlorid ch3 (formel I, R = C^, R1 = -C-CH3, R2 = CH3 i 4-stllling ) 5 iH3 1-[2-carbethoxy-4-(2-thienyl-carboxamido)-phenoxy]-3--isopropylamino-2-propanol (base) 10 ^H3 (formel I, amid i 2-stilling, R = C2H^ R1 = -CH-CH3) 1-[2-carbethoxy-4-(2-thienyl-carboxamido)-phenoxy]-3--tert.-butylamino-2-propanol (base)
15 CH3 (formel I, amid i 2-stilling, R = C2H3, = -C-CH3) CH3 1-[2-carbethoxy-4-(3-thienyl-carboxamido)-phenoxy]-20 -3-isopropylamino-2-propanol (base) x /CH3 (formel I, amid i 3-stilling, R = C0Hc, R = CH ) b V Xch3 25 1-[2-carbethoxy-4-(3-thienyl-carboxamido)-phenoxy]-3- -tert.-.butylamino-2-propanol (base) ch3 (formel I, amid i 3-stilling, R = C2H5' = ~C-CH3) cn3 30 1-[2-carbamethoxy-4-(2-thienyl-carboxamido)phenoxy]-3--tert.-butylamino-2-propanol (base) CH3
1. J 35 (formel I, amid i 2-stilling, R = CH3, R = C - CH3) ch3
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8212499 | 1982-07-16 | ||
| FR8212499A FR2530245A1 (fr) | 1982-07-16 | 1982-07-16 | Nouveaux 1-(2-carbalkoxy 4-(thienyl-alkylamido)phenoxy) 3-amino 2-propanols, leur preparation et leurs applications en therapeutique |
| FR8309361A FR2546890B2 (fr) | 1983-06-06 | 1983-06-06 | Nouveaux derives substitues du 1-(2-carbalkoxy 4-(thienyl carboxamido phenoxy) 3-amino 2-propanol, leur preparation et leurs applications en therapeutique |
| FR8309361 | 1983-06-06 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| DK326883D0 DK326883D0 (da) | 1983-07-15 |
| DK326883A DK326883A (da) | 1984-01-17 |
| DK164552B true DK164552B (da) | 1992-07-13 |
| DK164552C DK164552C (da) | 1992-11-30 |
Family
ID=26222995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK326883A DK164552C (da) | 1982-07-16 | 1983-07-15 | Analogifremgangsmaade til fremstilling af 1-oe2-carbalkoxy-4-(thienylcarboxamido)-phenoxyaa-3-amino-2-propanoler eller syreadditionssalte deraf |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4668801A (da) |
| EP (1) | EP0099822B1 (da) |
| AU (1) | AU566089B2 (da) |
| CA (1) | CA1205478A (da) |
| DE (1) | DE3367389D1 (da) |
| DK (1) | DK164552C (da) |
| ES (1) | ES524103A0 (da) |
| GR (1) | GR79194B (da) |
| IE (1) | IE56108B1 (da) |
| PT (1) | PT77031B (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5268389A (en) * | 1989-10-16 | 1993-12-07 | Uniroyal Chemical Company, Inc. | Thiocarboxylate ester compounds compositions containing the same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1543689A (fr) * | 1966-11-03 | 1968-10-25 | Ici Ltd | Procédé de fabrication de nouvelles alcanolamines et de leurs dérivés |
| GB1185044A (en) * | 1966-11-03 | 1970-03-18 | Ici Ltd | Alkanolamine Derivatives |
| GB1531718A (en) * | 1974-11-20 | 1978-11-08 | Pharmacia As | Phenylethanolamines |
| DE2923817C2 (de) * | 1979-06-12 | 1981-07-09 | A. Nattermann & Cie GmbH, 5000 Köln | (3-Alkylamino-2-hydroxyproposy)-furan-2-carbonsäureanilide und deren physiologisch verträgliche Säureadditionssalze und Verfahren zu deren Herstellung sowie Arzneimittel mit einem Gehalt dieser Verbindungen |
| FR2510573B1 (fr) * | 1981-07-29 | 1985-07-26 | Carpibem | (2-substitue 4-(thienyl acetamido) phenoxy) hydroxy propylamines, leur preparation, leur utilisation en therapeutique, et nouveaux intermediaires |
| ZA827646B (en) * | 1981-11-12 | 1983-08-31 | American Hospital Supply Corp | Esters of aryloxypropanolamine derivatives |
-
1983
- 1983-06-27 IE IE1496/83A patent/IE56108B1/en not_active IP Right Cessation
- 1983-07-05 GR GR71869A patent/GR79194B/el unknown
- 1983-07-13 EP EP83401450A patent/EP0099822B1/fr not_active Expired
- 1983-07-13 DE DE8383401450T patent/DE3367389D1/de not_active Expired
- 1983-07-14 ES ES524103A patent/ES524103A0/es active Granted
- 1983-07-14 PT PT77031A patent/PT77031B/pt unknown
- 1983-07-14 CA CA000432423A patent/CA1205478A/en not_active Expired
- 1983-07-15 DK DK326883A patent/DK164552C/da not_active IP Right Cessation
- 1983-07-15 AU AU16868/83A patent/AU566089B2/en not_active Ceased
-
1985
- 1985-12-23 US US06/814,077 patent/US4668801A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE3367389D1 (en) | 1986-12-11 |
| DK164552C (da) | 1992-11-30 |
| PT77031B (fr) | 1986-01-28 |
| US4668801A (en) | 1987-05-26 |
| CA1205478A (en) | 1986-06-03 |
| AU566089B2 (en) | 1987-10-08 |
| EP0099822B1 (fr) | 1986-11-05 |
| IE831496L (en) | 1984-01-16 |
| ES8407485A1 (es) | 1984-10-01 |
| IE56108B1 (en) | 1991-04-24 |
| AU1686883A (en) | 1984-01-19 |
| PT77031A (fr) | 1983-08-01 |
| EP0099822A1 (fr) | 1984-02-01 |
| GR79194B (da) | 1984-10-22 |
| ES524103A0 (es) | 1984-10-01 |
| DK326883A (da) | 1984-01-17 |
| DK326883D0 (da) | 1983-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK168535B1 (da) | 2,6-Dialkylphenylaminocarbonylmethyl-piperazinderivater, fremgangsmåde til fremstilling deraf, samt farmaceutisk præparat indeholdende disse derivater | |
| CY1671A (en) | A process for the preparation of 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-acetic acid and its dihydrochloride | |
| FI83768C (fi) | Foerfarande foer framstaellning av farmakologiskt aktiva substituerade bensamidderivat. | |
| NO162176B (no) | Middel for bekjempelse av plantesykdommer og anvendelse derav. | |
| JPWO1993012069A1 (ja) | 新規なアミノアルコール誘導体またはその塩 | |
| DK143128B (da) | Analogifremgan&smaade til fremstilling af 1-aryloxy-2-hydroxy-3-alkylaminopropaner eller deres fysiologisk acceptable syreadditionssalte | |
| CA2091248C (en) | Diphenylpiperazine derivative and drug for circulatory organ containing the same | |
| US4210653A (en) | Pyridyloxypropanolamines | |
| EP0318860B1 (en) | Substituted alkylamine derivatives | |
| SU545256A3 (ru) | Способ получени производных изохинолина или их солей | |
| US4595685A (en) | Benzothiazine derivatives | |
| DK164552B (da) | Analogifremgangsmaade til fremstilling af 1-oe2-carbalkoxy-4-(thienylcarboxamido)-phenoxyaa-3-amino-2-propanoler eller syreadditionssalte deraf | |
| WO1993012069A1 (fr) | Nouveau derive d'alcool amine ou son sel | |
| SU428602A3 (ru) | Способ получения основпозамещенных производных 1 | |
| US2679501A (en) | Amino derivatives of 2-substituted-4-tert. butylphenol ethers | |
| IE51576B1 (en) | Tetrazole derivatives | |
| NZ228046A (en) | Tertiary amines and medicaments | |
| US3850947A (en) | 3-thiazol-4'-oxy-aminopropanol cardiovascular agents | |
| SU439963A1 (ru) | Способ получени фениламиноалканов | |
| SU528035A3 (ru) | Способ получени производных изохинолина или их солей | |
| US3822266A (en) | (3-(1-piperazinyl)-2-hydroxy-propoxy)acetanilides | |
| US4738960A (en) | 1,3,4-Thiadiazole derivatives and pharmaceutical preparations useful as inhibitors for histamine-H2 receptors | |
| EP0297621A2 (en) | Cyclic amino-thioacetal amides, a process for the preparation thereof and pharmaceutical compositions containing them | |
| DK145225B (da) | Analogifremgangsmaade til fremstilling af 1-(3-trimethoxyphenoxy-2-hydroxy-propyl)-4-phenyl-piperazinderivater eller syreadditionssalte deraf | |
| DK157865B (da) | Fremgangsmaade til fremstilling af ranitidin og ethyleniminoderivat til anvendelse som udgangsmateriale ved fremgangsmaaden |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PBP | Patent lapsed |